Single nucleotide polymorphisms of 8 inflammation-related genes and their associations with smoking-related cancers
Sam S. Oh
Department of Epidemiology, University of California, Los Angeles (UCLA) School of Public Health, Los Angeles, CA
Search for more papers by this authorShen-Chih Chang
Department of Epidemiology, University of California, Los Angeles (UCLA) School of Public Health, Los Angeles, CA
Search for more papers by this authorLin Cai
Department of Epidemiology, School of Public Health, Fujian Medical University, Fuzhou, China
Search for more papers by this authorCarlos Cordon-Cardo
Herbert Irwing Comprehensive Cancer Center, Columbia University, New York, NY
Search for more papers by this authorBao-Guo Ding
Taixing City Center for Disease Control and Prevention (CDC), Taixing City, Jiangsu, China
Search for more papers by this authorSander Greenland
Department of Epidemiology, University of California, Los Angeles (UCLA) School of Public Health, Los Angeles, CA
Department of Statistics, UCLA, Los Angeles, CA
Search for more papers by this authorNa He
Fudan University School of Public Health, Shanghai, China
Search for more papers by this authorQingwu Jiang
Fudan University School of Public Health, Shanghai, China
Search for more papers by this authorLeeka Kheifets
Department of Epidemiology, University of California, Los Angeles (UCLA) School of Public Health, Los Angeles, CA
Search for more papers by this authorAnh Le
School of Dentistry, University of Southern California, Los Angeles, CA
Search for more papers by this authorYuan-Chin Amy Lee
Department of Epidemiology, University of California, Los Angeles (UCLA) School of Public Health, Los Angeles, CA
Search for more papers by this authorSimin Liu
Department of Epidemiology, University of California, Los Angeles (UCLA) School of Public Health, Los Angeles, CA
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA
Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA
Center for Metabolic Disease Prevention, UCLA, Los Angeles, CA
Search for more papers by this authorMing-Lan Lu
Departments of Pathology and Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
Search for more papers by this authorJenny T. Mao
Pulmonary and Critical Care Section, New Mexico VA Healthcare System, Albuquerque, NM
Search for more papers by this authorHal Morgenstern
Department of Epidemiology, University of Michigan, Ann Arbor, MI
Department of Environmental Health Sciences, University of Michigan, Ann Arbor, MI
Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI
Search for more papers by this authorLi-Na Mu
Department of Social and Preventive Medicine, State University of New York (SUNY) at Buffalo, NY
Search for more papers by this authorAllan Pantuck
Department of Urology, UCLA David Geffen School of Medicine, Los Angeles, CA
Search for more papers by this authorJeanette C. Papp
Department of Human Genetics, UCLA, Los Angeles, CA
Search for more papers by this authorSungshim Lani Park
Department of Epidemiology, University of California, Los Angeles (UCLA) School of Public Health, Los Angeles, CA
Search for more papers by this authorJian Yu Rao
Department of Epidemiology, University of California, Los Angeles (UCLA) School of Public Health, Los Angeles, CA
Department of Pathology and Laboratory Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA
Search for more papers by this authorVictor E. Reuter
Departments of Pathology and Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
Search for more papers by this authorDonald P. Tashkin
Division of Pulmonary and Critical Care Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA
Search for more papers by this authorNai-Chieh Y. You
Department of Epidemiology, University of California, Los Angeles (UCLA) School of Public Health, Los Angeles, CA
Search for more papers by this authorShun-Zhang Yu
Fudan University School of Public Health, Shanghai, China
Search for more papers by this authorArie Belldegrun
Department of Urology, UCLA David Geffen School of Medicine, Los Angeles, CA
Search for more papers by this authorCorresponding Author
Zuo-Feng Zhang
Department of Epidemiology, University of California, Los Angeles (UCLA) School of Public Health, Los Angeles, CA
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA
Tel.: 310-825-8418, Fax: 310-206-6039
Department of Epidemiology, School of Public Health, University of California, Los Angeles, 71-225 CHS, Box 951772, 650 Charles E Young Drive, South, Los Angeles, CA 90095-1772, USASearch for more papers by this authorSam S. Oh
Department of Epidemiology, University of California, Los Angeles (UCLA) School of Public Health, Los Angeles, CA
Search for more papers by this authorShen-Chih Chang
Department of Epidemiology, University of California, Los Angeles (UCLA) School of Public Health, Los Angeles, CA
Search for more papers by this authorLin Cai
Department of Epidemiology, School of Public Health, Fujian Medical University, Fuzhou, China
Search for more papers by this authorCarlos Cordon-Cardo
Herbert Irwing Comprehensive Cancer Center, Columbia University, New York, NY
Search for more papers by this authorBao-Guo Ding
Taixing City Center for Disease Control and Prevention (CDC), Taixing City, Jiangsu, China
Search for more papers by this authorSander Greenland
Department of Epidemiology, University of California, Los Angeles (UCLA) School of Public Health, Los Angeles, CA
Department of Statistics, UCLA, Los Angeles, CA
Search for more papers by this authorNa He
Fudan University School of Public Health, Shanghai, China
Search for more papers by this authorQingwu Jiang
Fudan University School of Public Health, Shanghai, China
Search for more papers by this authorLeeka Kheifets
Department of Epidemiology, University of California, Los Angeles (UCLA) School of Public Health, Los Angeles, CA
Search for more papers by this authorAnh Le
School of Dentistry, University of Southern California, Los Angeles, CA
Search for more papers by this authorYuan-Chin Amy Lee
Department of Epidemiology, University of California, Los Angeles (UCLA) School of Public Health, Los Angeles, CA
Search for more papers by this authorSimin Liu
Department of Epidemiology, University of California, Los Angeles (UCLA) School of Public Health, Los Angeles, CA
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA
Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA
Center for Metabolic Disease Prevention, UCLA, Los Angeles, CA
Search for more papers by this authorMing-Lan Lu
Departments of Pathology and Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
Search for more papers by this authorJenny T. Mao
Pulmonary and Critical Care Section, New Mexico VA Healthcare System, Albuquerque, NM
Search for more papers by this authorHal Morgenstern
Department of Epidemiology, University of Michigan, Ann Arbor, MI
Department of Environmental Health Sciences, University of Michigan, Ann Arbor, MI
Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI
Search for more papers by this authorLi-Na Mu
Department of Social and Preventive Medicine, State University of New York (SUNY) at Buffalo, NY
Search for more papers by this authorAllan Pantuck
Department of Urology, UCLA David Geffen School of Medicine, Los Angeles, CA
Search for more papers by this authorJeanette C. Papp
Department of Human Genetics, UCLA, Los Angeles, CA
Search for more papers by this authorSungshim Lani Park
Department of Epidemiology, University of California, Los Angeles (UCLA) School of Public Health, Los Angeles, CA
Search for more papers by this authorJian Yu Rao
Department of Epidemiology, University of California, Los Angeles (UCLA) School of Public Health, Los Angeles, CA
Department of Pathology and Laboratory Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA
Search for more papers by this authorVictor E. Reuter
Departments of Pathology and Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
Search for more papers by this authorDonald P. Tashkin
Division of Pulmonary and Critical Care Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA
Search for more papers by this authorNai-Chieh Y. You
Department of Epidemiology, University of California, Los Angeles (UCLA) School of Public Health, Los Angeles, CA
Search for more papers by this authorShun-Zhang Yu
Fudan University School of Public Health, Shanghai, China
Search for more papers by this authorArie Belldegrun
Department of Urology, UCLA David Geffen School of Medicine, Los Angeles, CA
Search for more papers by this authorCorresponding Author
Zuo-Feng Zhang
Department of Epidemiology, University of California, Los Angeles (UCLA) School of Public Health, Los Angeles, CA
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA
Tel.: 310-825-8418, Fax: 310-206-6039
Department of Epidemiology, School of Public Health, University of California, Los Angeles, 71-225 CHS, Box 951772, 650 Charles E Young Drive, South, Los Angeles, CA 90095-1772, USASearch for more papers by this authorAbstract
Tobacco smoke and its metabolites are carcinogens that increase tissue oxidative stress and induce target tissue inflammation. We hypothesized that genetic variation of inflammatory pathway genes plays a role in tobacco-related carcinogenesis and is modified by tobacco smoking. We evaluated the association of 12 single nucleotide polymorphisms of 8 inflammation-related genes with tobacco-related cancers (lung, oropharynx, larynx, esophagus, stomach, liver, bladder, and kidney) using 3 case-control studies from: Los Angeles (population-based; 611 lung and 553 upper aero-digestive tract cancer cases and 1,040 controls), Taixing, China (population-based; 218 esophagus, 206 stomach, 204 liver cancer cases, and 415 controls), and Memorial Sloan-Kettering Cancer Center (hospital-based; 227 bladder cancer cases and 211 controls). After adjusting for age, education, ethnicity, gender, and tobacco smoking, IL10 rs1800871 was inversely associated with oropharyngeal cancer (CT+TT vs. CC adjusted odds ratio [aOR]: 0.69, 95% confidence interval [CI]: 0.50–0.95), and was positively associated with lung cancer among never smokers (TT vs. CT+CC aOR: 2.5, 95% CI: 1.3–5.1) and inversely with oropharyngeal cancer among ever smokers (CT+TT vs. CC aOR: 0.63, 95% CI: 0.41–0.95). Among all pooled never smokers (588 cases and 816 controls), TNF rs1799964 was inversely associated with smoking-related cancer (CC vs. CT+TT aOR: 0.36, 95% CI: 0.17–0.77). Bayesian correction for multiple comparisons suggests that chance is unlikely to explain our findings (although epigenetic mechanisms may be in effect), which support our hypotheses, suggesting that IL10 rs1800871 is a susceptibility marker for oropharyngeal and lung cancers, and that TNF rs1799964 is associated with smoking-related cancers among never smokers.
Supporting Information
Additional Supporting Information may be found in the online version of this article.
| Filename | Description |
|---|---|
| IJC_25214_sm_suptable.doc1.2 MB | Supporting Table 1 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1 Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323: 1228–33.
- 2 Alberg AJ, Ford JG, Samet JM, American College of Chest Physicians. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines. (2nd edition) Chest 2007; 132: 29S–55.
- 3 Engels EA. Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther 2008; 8: 605–15.
- 4 Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030–44.
- 5 Gorouhi F, Islami F, Bahrami H, Kamangar F. Tumour-necrosis factor-A polymorphisms and gastric cancer risk: a meta-analysis. Br J Cancer 2008; 98: 1443–51.
- 6 Wang SS, Cerhan JR, Hartge P, Davis S, Cozen W, Severson RK, Chatterjee N, Yeager M, Chanock SJ, Rothman N. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res 2006; 66: 9771–80.
- 7 Taioli E. Gene-environment interaction in tobacco-related cancers. Carcinogenesis 2008; 29: 1467–74.
- 8 Wu X, Zhao H, Suk R, Christiani DC. Genetic susceptibility to tobacco-related cancer. Oncogene 2004; 23: 6500–23.
- 9 Hussain SK, Madeleine MM, Johnson LG, Du Q, Malkki M, Wilkerson HW, Farin FM, Carter JJ, Galloway DA, Daling JR, Petersdorf EW, Schwartz SM. Cervical and vulvar cancer risk in relation to the joint effects of cigarette smoking and genetic variation in interleukin 2. Cancer Epidemiol Biomarkers Prev 2008; 17: 1790–9.
- 10 Wang H, Tan W, Hao B, Miao X, Zhou G, He F, Lin D. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res 2003; 63: 8057–61.
- 11 Hashibe M, Morgenstern H, Cui Y, Tashkin DP, Zhang ZF, Cozen W, Mack TM, Greenland S. Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2006; 15: 1829–34.
- 12 Mu LN, Lu QY, Yu SZ, Jiang QW, Cao W, You NC, Setiawan VW, Zhou XF, Ding BG, Wang RH, Zhao J, Cai L, et al. Green tea drinking and multigenetic index on the risk of stomach cancer in a Chinese population. Int J Cancer 2005; 116: 972–83.
- 13 Cao W, Cai L, Rao JY, Pantuck A, Lu ML, Dalbagni G, Reuter V, Scher H, Cordon-Cardo C, Figlin RA, Belldegrun A, Zhang ZF. Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma. Cancer 2005; 104: 2400–8.
- 14 Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001; 29: 308–11.
- 15 Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96: 434–42.
- 16 Wakefield J. A Bayesian measure of the probability of false discovery in genetic epidemiology studies. Am J Hum Genet 2007; 81: 208–27.
- 17 Vogel U, Christensen J, Wallin H, Friis S, Nexo BA, Raaschou-Nielsen O, Overvad K, Tjonneland A. Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res 2008; 639: 89–100.
- 18 Van Dyke AL, Cote ML, Wenzlaff AS, Chen W, Abrams J, Land S, Giroux CN, Schwartz AG. Cytokine and cytokine receptor single-nucleotide polymorphisms predict risk for non-small cell lung cancer among women. Cancer Epidemiol Biomarkers Prev 2009; 18: 1829–40.
- 19 Shih C-M, Lee Y-L, Chiou H-L, Hsu W-F, Chen W-E, Chou M-C, Lin L-Y. The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer. Lung Cancer 2005; 50: 291–7.
- 20 Hosgood HD, III, Menashe I, Shen M, Yeager M, Yuenger J, Rajaraman P, He X, Chatterjee N, Caporaso NE, Zhu Y, Chanock SJ, Zheng T, et al. Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway. Carcinogenesis 2008; 29: 1938–43.
- 21 Engels EA, Wu X, Gu J, Dong Q, Liu J, Spitz MR. Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res 2007; 67: 6520–7.
- 22 Fujieda S, Sunaga H, Tsuzuki H, Fan GK, Saito H. IL-10 expression is associated with the expression of platelet-derived endothelial cell growth factor and prognosis in oral and oropharyngeal carcinoma. Cancer Lett 1999; 136: 1–9.
- 23 Chandler SW, Rassekh CH, Rodman SM, Ducatman BS. Immunohistochemical localization of interleukin-10 in human oral and pharyngeal carcinomas. Laryngoscope 2002; 112: 808–15.
- 24 Reichert S, Machulla HK, Klapproth J, Zimmermann U, Reichert Y, Glaser CH, Schaller HG, Stein J, Schulz S. The interleukin-10 promoter haplotype ATA is a putative risk factor for aggressive periodontitis. J Periodontal Res 2008; 43: 40–7.
- 25 Sumer AP, Kara N, Keles GC, Gunes S, Koprulu H, Bagci H. Association of interleukin-10 gene polymorphisms with severe generalized chronic periodontitis. J Periodontol 2007; 78: 493–7.
- 26 Tezal M, Sullivan MA, Reid ME, Marshall JR, Hyland A, Loree T, Lillis C, Hauck L, Wactawski-Wende J, Scannapieco FA. Chronic periodontitis and the risk of tongue cancer. Arch Otolaryngol Head Neck Surg 2007; 133: 450–4.
- 27 Tezal M, Grossi SG, Genco RJ. Is periodontitis associated with oral neoplasms? J Periodontol 2005; 76: 406–10.
- 28 Vairaktaris E, Yapijakis C, Serefoglou Z, Avgoustidis D, Critselis E, Spyridonidou S, Vylliotis A, Derka S, Vassiliou S, Nkenke E, Patsouris E. Gene expression polymorphisms of interleukins-1 beta, −4, −6, −8, −10, and tumor necrosis factors-alpha, -beta: regression analysis of their effect upon oral squamous cell carcinoma. J Cancer Res Clin Oncol 2008; 134: 821–32.
- 29 Yao JG, Gao LB, Liu YG, Li J, Pang GF. Genetic variation in interleukin-10 gene and risk of oral cancer. Clin Chim Acta 2008; 388: 84–8.
- 30 Asada M, Yasuda H, Ebihara S, Tomita N, Suzuki S, Sato M, Kubo H, Yamaya M. Interleukin-1beta gene polymorphisms associated with risk of lung cancer in Japanese. Lung Cancer 2006; 54: 261–3.
- 31 Zienolddiny S, Ryberg D, Maggini V, Skaug V, Canzian F, Haugen A. Polymorphisms of the interleukin-1 beta gene are associated with increased risk of non-small cell lung cancer. Int J Cancer 2004; 109: 353–6.
- 32 Lee KM, Shen M, Chapman RS, Yeager M, Welch R, He X, Zheng T, Hosgood HD, Yang D, Berndt SI, Chanock S, Lan Q. Polymorphisms in immunoregulatory genes, smoky coal exposure and lung cancer risk in Xuan Wei. China. Carcinogenesis 2007; 28: 1437–41.
- 33 Campa D, Hung RJ, Mates D, Zaridze D, Szeszenia-Dabrowska N, Rudnai P, Lissowska J, Fabianova E, Bencko V, Foretova L, Janout V, Boffetta P, et al. Lack of association between polymorphisms in inflammatory genes and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2005; 14: 538–9.
- 34 Hu Z, Shao M, Chen Y, Zhou J, Qian J, Xu L, Ma H, Wang X, Xu Y, Lu D, Shen H. Allele 2 of the interleukin-1 receptor antagonist gene (IL1RN*2) is associated with a decreased risk of primary lung cancer. Cancer Lett 2006; 236: 269–75.
- 35 Lind H, Zienolddiny S, Ryberg D, Skaug V, Phillips DH, Haugen A. Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1 beta gene. Lung Cancer 2005; 50: 285–90.
- 36 Chanudet E, Ye H, Ferry J, Bacon CM, Adam P, Muller-Hermelink HK, Radford J, Pileri SA, Ichimura K, Collins VP, Hamoudi RA, Nicholson AG, et al. A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands. J Pathol 2009; 217: 420–30.
- 37 Morgan GJ, Adamson PJ, Mensah FK, Spink CF, Law GR, Keen LJ, Roman E, Davies FE, Rollinson S, Child JA, Bidwell JL. Haplotypes in the tumour necrosis factor region and myeloma. Br J Haematol 2005; 129: 358–65.
- 38 Seifart C, Plagens A, Dempfle A, Clostermann U, Vogelmeier C, von Wichert P, Seifart U. TNF-alpha. TNF-beta. IL-6, and. IL-10 polymorphisms in patients with lung cancer. Dis Markers 2005; 21: 157–65.
- 39 Shih CM, Lee YL, Chiou HL, Chen W, Chang GC, Chou MC, Lin LY. Association of TNF-alpha polymorphism with susceptibility to and severity of non-small cell lung cancer. Lung Cancer 2006; 52: 15–20.
- 40 Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, Tardon A, Serra C, Carrato A, Garcia-Closas R, Lloreta J, Castano-Vinyals G, et al. NAT2 slow acetylation. GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005; 366: 649–59.
- 41 Marcus PM, Hayes RB, Vineis P, Garcia-Closas M, Caporaso NE, Autrup H, Branch RA, Brockmoller J, Ishizaki T, Karakaya AE, Ladero JM, Mommsen S, et al. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev 2000; 9: 461–7.
- 42 Engstrom PF, Clapper M, Schnoll RA, Orleans CT. Prevention of tobacco-related cancers. In: DW Kufe, RE Pollock, RR Weichselbaum, RC Bast, TS Gansler, eds. Cancer medicine, 6th edn. Hamilton, Ontario: B.C. Decker, 2003.
- 43 Kinane DF, Chestnutt IG. Smoking and periodontal disease. Crit Rev Oral Biol Med 2000; 11: 356–65.
- 44 Ji L, Melkonian G, Riveles K, Talbot P. Identification of pyridine compounds in cigarette smoke solution that inhibit growth of the chick chorioallantoic membrane. Toxicol Sci 2002; 69: 217–25.
- 45 Melkonian G, Cheung L, Marr R, Tong C, Talbot P. Mainstream and sidestream cigarette smoke inhibit growth and angiogenesis in the day 5 chick chorioallantoic membrane. Toxicol Sci 2002; 68: 237–48.
- 46 Hasnis E, Bar-Shai M, Burbea Z, Reznick AZ. Mechanisms underlying cigarette smoke-induced NF-kappaB activation in human lymphocytes: the role of reactive nitrogen species. J Physiol Pharmacol 2007; 58 ( Suppl 5): 275–87.
- 47 Kitamura M, Kasai A. Cigarette smoke as a trigger for the dioxin receptor-mediated signaling pathway. Cancer Lett 2007; 252: 184–94.
- 48 Pryor WA, Prier DG, Church DF. Electron-spin resonance study of mainstream and sidestream cigarette smoke: nature of the free radicals in gas-phase smoke and in cigarette tar. Environ Health Perspect 1983; 47: 345–55.
- 49 Brody JS, Spira A. State of the art. Chronic obstructive pulmonary disease, inflammation, and lung cancer. Proc Am Thorac Soc 2006; 3: 535–7.
- 50 Posch PE, Cruz I, Bradshaw D, Medhekar BA. Novel polymorphisms and the definition of promoter ‘alleles’ of the tumor necrosis factor and lymphotoxin alpha loci: inclusion in HLA haplotypes. Genes Immun 2003; 4: 547–58.
- 51 Smith AJ, Humphries SE. Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev 2009; 20: 43–59.
- 52 Fargion S, Valenti L, Dongiovanni P, Fracanzani AL. TNFalpha promoter polymorphisms. Methods Mol Med 2004; 98: 47–58.
- 53 Higuchi T, Seki N, Kamizono S, Yamada A, Kimura A, Kato H, Itoh K. Polymorphism of the 5′-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens 1998; 51: 605–12.
- 54 Ryder MI, Saghizadeh M, Ding Y, Nguyen N, Soskolne A. Effects of tobacco smoke on the secretion of interleukin-1beta, tumor necrosis factor-alpha, and transforming growth factor-beta from peripheral blood mononuclear cells. Oral Microbiol Immunol 2002; 17: 331–6.
- 55 Rady PL, Matalon R, Grady J, Smith EM, Hudnall SD, Kellner LH, Nitowsky H, Tyring SK, Hughes TK. Comprehensive analysis of genetic polymorphisms in the interleukin-10 promoter: implications for immune regulation in specific ethnic populations. Genetic Testing 2004; 8: 194–203.
- 56 Suárez A, Castro P, Alonso R, Mozo L, Gutiérrez C. Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation 2003; 75: 711–17.
- 57 Nielsen KB, Sorensen S, Cartegni L, Corydon TJ, Doktor TK, Schroeder LD, Reinert LS, Elpeleg O, Krainer AR, Gregersen N, Kjems J, Andresen BS. Seemingly neutral polymorphic variants may confer immunity to splicing-inactivating mutations: a synonymous SNP in exon 5 of MCAD protects from deleterious mutations in a flanking exonic splicing enhancer. Am J Hum Genet 2007; 80: 416–32.
- 58 Wang D, Johnson AD, Papp AC, Kroetz DL, Sadée W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 2005; 15: 693–704.
- 59 Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, Maixner W, Diatchenko L. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 2006; 314: 1930–3.
- 60 Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315: 525–8.
- 61 Rothman KJ, Greenland S, Lash TL. Modern epidemiology, 3rd edn. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2008.
- 62 Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004; 4: 143–53.
- 63
Schottenfeld D,
Fraumeni JF.
Cancer epidemiology and prevention,
3rd edn.
Oxford; New York:
Oxford University Press,
2006.
10.1093/acprof:oso/9780195149616.001.0001 Google Scholar
Citing Literature
